• Korean Journal of Plant Taxonomy
• /
• v.36 no.4
• /
• pp.279-292
• /
• 2006

Patterns of morphological variation in Cirsium japonicum complex were examined using numerical analysis, and the delimitation of taxa was evaluated. Principal components analysis of taxa using 24 morphological characters and 11 leaf characters revealed the presence of two major groups; C. japonicum var. japonicum and C. japonicum var. spinosissimum. Circium japonicum f. nakaianum could be included in the category of C. japonicum var. japonicum. In conclusion, Korean C. japonicum complex was composed of two varieties and one form, C. Japonicum var. japonicum, C. japonicum var. spinosissimum, and C. japonicum var. spinosissimum f. alba.

• YAKHAK HOEJI
• /
• v.50 no.6
• /
• pp.429-435
• /
• 2006

The antidepressant effects of Cirsium japonicum compositae was investigated using open field test and forced swimming test. Total extract of Cirsium japonicum (CJ) was orally administered at dose of 20, 100, 300, 500 mg/kg bodyweight. Supplementation of CJ increased dose-dependently movement, rearing frequency and total turn angle in the center area of open field in mice. Treatment of Cirsium japonicum's extract (300 mg/kg, CJ) decreased immobile duration and increased mobile and strong mobile duration significantly; and it is comparable to that of imipramine and fluoxetine. These results indicate that CJ has antidepressant effect. Treatment of CJ did not induced any impairment in motor coordination and myorelaxation. These results indicate that the constituents or its complex of Cirsium japonicum could be a candidate of new antidepressant drug.

• Journal of the Korean Society of Food Science and Nutrition
• /
• v.45 no.6
• /
• pp.903-910
• /
• 2016

In this study, the expression level of estrogen receptor in an ovariectomized rat model was effectively enhanced by MS-10, Cirsium japonicum and Thymus vulgaris extract complex, in a reversible manner. MS-10 plays a positive role in enhancing estrogen activity at low concentrations, leading to improved women's health. In order to determine whether or not MS-10 improves menopausal symptoms clinically, a randomized, double-blinded, and placebo-controlled clinical study was carried out on 62 middle-aged women treated with 500 mg of MS-10 or placebo daily for 12 weeks. Clinical menopausal symptoms were evaluated by Kupperman's index (KI) detecting various menopausal symptoms, including hot flushes, parenthesis, insomnia, nervousness, melancholia, dizziness, fatigue, rheumatic pain, palpitations, formication, and headaches. Total KI score decreased significantly by about 18% upon ingestion of MS-10. Colpoxerosis, a main symptom of menopause, was significantly reduced by about 21% upon ingestion of MS-10 in contrast to placebo. In addition, reduction of insulin-like growth factor-1 with age was improved by over 10% upon ingestion of MS-10, whereas there were no significant difference with placebo. No side effects appeared after treatment with MS-10. Thus, MS-10 can be suggested as a plausible natural substance for improving women's health.